Brief: Oncocyte Presents Determaio™ Data At Asco 2022 Supporting The Test’S Potential To Expand The Clinical Use Of Immunotherapy

Insight Molecular Diagnostics

27/05/2022 24:43

May 26 (Reuters) - OncoCyte Corp  OCX.O :
    * ONCOCYTE PRESENTS DETERMAIO™ DATA AT ASCO 2022 SUPPORTING
THE
TEST’S POTENTIAL TO EXPAND THE CLINICAL USE OF IMMUNOTHERAPY
    * ONCOCYTE CORP - DETERMAIO TEST NOW VALIDATED BY 10 STUDIES
IN
SIX TUMOR TYPES ACROSS FOUR LEADING IMMUNE CHECKPOINT INHIBITORS

Source text for Eikon:  ID:nGNX3Rx9zL 
Further company coverage:  OCX.O 

 ((Reuters.Briefs@thomsonreuters.com;))